This Week in Cardiology

 
 

  • Jan 27 2023 This Week in Cardiology   Exercise for AF, drugs have more than one effect, AI bots and the future of medicine, and the good and bad news about prognosis in HF are the topics John Mandrola, MD, discusses in this week's podcast.
  • Jan 20 2023 This Week in Cardiology   The loop diuretic duels, adverse events during hospital admissions, BP accuracy, and left main revascularization strategies (again) are the topics John Mandrola discusses in this week’s podcast.
  • Jan 13 2023 This Week in Cardiology   FOURIER authors' response, a possible practice-changing paper in electrophysiology, and the ATLAS and CAPLA trials are the topics John Mandrola, MD, discusses in this week’s podcast.
  • Jan 6 2023 This Week in Cardiology   Damar Hamlin, obesity and semaglutide, Open Data and PCSK9 inhibitors, and TAVI vs SAVR trials are the topics John Mandrola, MD, discusses in this week’s podcast.
  • Dec 23 2022 This Week in Cardiology   The top ten stories of the year plus a few honorary mentions.
  • Dec 16 2022 This Week in Cardiology   BP control over the long term, omecamtiv mecarbil, incentives and Goodhart’s law, and open science are the topics John Mandrola, MD, covers in this week’s podcast.
  • Dec 9 2022 This Week in Cardiology   Nudges, statins, AI, less-is-more in the ICU, myocarditis, exercise as medicine, and December in the hospital are the topics John Mandrola, MD, covers in this week’s podcast.
  • Dec 2 2022 This Week in Cardiology   SGLT2 inhibitors, publishing choices, second and third order effects of interventions, decision support, and patient selection for preventive procedures are the topics John Mandrola, MD, discusses in this week’s podcast.
  • Nov 18 2022 This Week in Cardiology   AHA 2022, Part 2: IRONMAN, ECMO-CS, CTS-AMI, and PROGRESSIVE AF are the trials John Mandrola, MD, reviews in this week’s podcast.
  • Nov 11 2022 This Week in Cardiology   AHA 2022 Part 1: ISCHEMIA-EXTEND, STRONG-HF, chlorthalidone vs HCTZ, experts vs practitioners; torsemide vs furosemide; and TG lowering are discussed by John Mandrola, MD, in this week’s podcast.
  • Nov 4 2022 This Week in Cardiology   AF conversion in the ED, HRT, a shining example of evidence-based medicine and less-is-more, multimorbidity, and what’s coming at AHA are the topics John Mandrola, MD, covers in this week’s podcast.
  • Oct 28 2022 This Week in Cardiology   ERASE AF follow-up, recreational drugs and AF, etripamil, misuse of science, and diabetes as a cardiovascular risk factor are the topics John Mandrola, MD, discusses in this week's podcast.
  • Oct 21 2022 This Week in Cardiology   The ERASE AF ablation trial, left bundle pacing, finerenone, and perceptions of cardiology are the topics John Mandrola, MD, discusses in this week’s podcast.
  • Oct 14 2022 This Week in Cardiology  
  • Oct 7 2022 This Week in Cardiology   Post-PCI antiplatelet therapy, palliative care in patients with HF, Watchman information on hospital websites, and HCM in athletes are the topics John Mandrola, MD, covers in this week's podcast.
  • Sep 30 2022 This Week in Cardiology   Pulmonary embolism, coffee, when DOACs don’t work, lipoprotein (a), and the marginal benefits of current CV therapy are the topics John Mandrola, MD, discusses in this week’s podcast.
  • Sep 23 2022 This Week in Cardiology   The PROTECTED TAVR trial of an embolic protection device, renal denervation for hypertension, percutaneouls left atrial appendage closure, and deprescribing aspirin are discussed in this weeks podcast.
  • Sep 16 This Week in Cardiology   The safety of very low LDL-C, the win-ratio analytic method, sacubitril/valsartan, SGLT2 inhibitors, and percutaneous left atrial appendage closure are discussed in this week’s podcast.
  • Sep 9 2022 This Week in Cardiology   A potential new anticoagulant, surveillance stress testing, a trial misinterpretation, an old diuretic, and AI in cardiology are the topics John Mandrola, MD, discusses in this week’s podcast.
  • Sep 2 2022 This Week in Cardiology   A second ESC review covering REVIVED, the DANCAVAS CV screening trial, DELIVER on dapagliflozin in HF with mildly reduced EF, and the INVICTUS trial of rivaroxaban in rheumatic heart disease.